Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
J Virol ; 75(22): 10892-905, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11602729

ABSTRACT

The identification and epitope mapping of broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies (Abs) is important for vaccine design, but, despite much effort, very few such Abs have been forthcoming. Only one broadly neutralizing anti-gp41 monoclonal Ab (MAb), 2F5, has been described. Here we report on two MAbs that recognize a region immediately C-terminal of the 2F5 epitope. Both MAbs were generated from HIV-1-seropositive donors, one (Z13) from an antibody phage display library, and one (4E10) as a hybridoma. Both MAbs recognize a predominantly linear and relatively conserved epitope, compete with each other for binding to synthetic peptide derived from gp41, and bind to HIV-1(MN) virions. By flow cytometry, these MAbs appear to bind relatively weakly to infected cells and this binding is not perturbed by pretreatment of the infected cells with soluble CD4. Despite the apparent linear nature of the epitopes of Z13 and 4E10, denaturation of recombinant envelope protein reduces the binding of these MAbs, suggesting some conformational requirements for full epitope expression. Most significantly, Z13 and 4E10 are able to neutralize selected primary isolates from diverse subtypes of HIV-1 (e.g., subtypes B, C, and E). The results suggest that a rather extensive region of gp41 close to the transmembrane domain is accessible to neutralizing Abs and could form a useful target for vaccine design.


Subject(s)
Antibodies, Monoclonal/immunology , HIV Antibodies/immunology , HIV Envelope Protein gp41/immunology , HIV-1/immunology , Amino Acid Motifs , Amino Acid Sequence , Antibody Specificity , Enzyme-Linked Immunosorbent Assay , Epitopes , Flow Cytometry , HIV Envelope Protein gp41/chemistry , Humans , Molecular Sequence Data , Neutralization Tests
2.
J Virol ; 75(5): 2235-45, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11160727

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) neutralization occurs when specific antibodies, mainly those directed against the envelope glycoproteins, inhibit infection, most frequently by preventing the entry of the virus into target cells. However, the precise mechanisms of neutralization remain unclear. Previous studies, mostly with cell lines, have produced conflicting results involving either the inhibition of virus attachment or interference with postbinding events. In this study, we investigated the mechanisms of neutralization by immune sera and compared the inhibition of peripheral blood mononuclear cells (PBMC) infection by HIV-1 primary isolates (PI) with the inhibition of T-cell line infection by T-cell line-adapted (TCLA) strains. We followed the kinetics of neutralization to determine at which step of the viral cycle the antibodies act. We found that neutralization of the TCLA strain HIV-1MN/MT-4 required an interaction between antibodies and cell-free virions before the addition of MT-4 cells, whereas PI were neutralized even after adsorption onto PBMC. In addition, the dose-dependent inhibition of HIV-1MN binding to MT-4 cells was strongly correlated with serum-induced neutralization. In contrast, neutralizing sera did not reduce the adhesion of PI to PBMC. Postbinding inhibition was also detected for HIV-1MN produced by and infecting PBMC, demonstrating that the mechanism of neutralization depends on the target cell used in the assay. Finally, we considered whether the different mechanisms of neutralization may reflect the recognition of qualitatively different epitopes on the surface of PI and HIV-1MN or whether they reflect differences in virus attachment to PBMC and MT-4 cells.


Subject(s)
HIV Antibodies/immunology , HIV-1/immunology , HIV-1/physiology , Leukocytes, Mononuclear/virology , T-Lymphocytes/virology , Adsorption , Cell Line , HIV Core Protein p24/analysis , Humans , Immune Sera/immunology , Kinetics , Neutralization Tests , Virion/physiology
3.
Virology ; 280(2): 292-300, 2001 Feb 15.
Article in English | MEDLINE | ID: mdl-11162843

ABSTRACT

We describe the production and properties of a permanent cell line, CEM.NKR-CCR5-Luc. This line is a derivative of the CEM.NKR-CCR5 line, stably transfected to express the luciferase reporter gene under the transcriptional control of the HIV-2 LTR. Thus the cells respond to Tat expression during HIV-1 infection by producing luciferase, a protein that can be readily and accurately quantitated in a luminometer. The CEM.NKR-CCR5-Luc line expresses both the CCR5 and CXCR4 coreceptors and can therefore be infected with a range of HIV-1 isolates, irrespective of their tropism properties. This is true of HIV-1 isolates from several genetic subtypes and also of a group O isolate. Furthermore, luciferase expression is also activated by infection of the cells with SIVmac239 or SIVmac251. We show that the CEM.NKR-CCR5-Luc cells can be used in assays of HIV-1 neutralization and also for identifying inhibitors of HIV-1 entry targeted at the CCR5 and CXCR4 coreceptors. The luciferase end point simplifies the performance of neutralization and inhibitor-screening assays compared to the use of more conventional end points such as the detection of extracellular p24 antigen.


Subject(s)
Anti-HIV Agents/pharmacology , Antibodies, Viral/immunology , CCR5 Receptor Antagonists , Drug Evaluation, Preclinical/methods , Genes, Reporter , HIV-1/drug effects , HIV-1/immunology , Luciferases/genetics , Receptors, CXCR4/antagonists & inhibitors , T-Lymphocytes/virology , Amides/pharmacology , Benzylamines , Cell Line , Cell Line, Transformed , Cyclams , Gene Expression , HIV Core Protein p24/metabolism , HIV-1/isolation & purification , HIV-1/physiology , Heterocyclic Compounds/pharmacology , Humans , Neutralization Tests , Quaternary Ammonium Compounds/pharmacology , Receptors, CCR5/genetics , Receptors, CCR5/metabolism , T-Lymphocytes/cytology
4.
Bull Acad Natl Med ; 184(1): 67-84; discussion 85-7, 2000.
Article in French | MEDLINE | ID: mdl-10989532

ABSTRACT

Six Rhesus macaques were hyperimmunized with either live infectious human immunodeficiency virus type 1 (HIV-1) or with beta-propiolactone--or formalin--inactivated HIV-1. The virus used was HIV-1 BX08, a primary virus isolate grown in human PBMC. Instead of eliciting virus-neutralizing antibodies, this regimen induced antibodies that enhanced HIV-1 infectivity for PBMC by 10 to 90 fold. Enhancement was also seen in a cell-to-cell fusion assay using a Semliki Forest virus replicon to express BX08 gp160 in CD4+, CCR5+ HeLa cell cultures. These observations raise the concern that whole virus particles-based HIV-1 vaccines might elicit enhancing antibodies that could play a facilitating role in the transmission and/or evolution of the disease.


Subject(s)
Antibody-Dependent Enhancement/immunology , HIV-1/immunology , Immunization , Macaca/immunology , Virion/isolation & purification , Animals , Male
5.
J Virol ; 72(12): 9855-64, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9811721

ABSTRACT

Previous studies characterized the third variable (V3) loop of the envelope gp120 as the principal neutralizing determinant for laboratory T-cell-line-adapted (TCLA) strains of human immunodeficiency virus type 1 (HIV-1). However, primary viruses isolated from infected individuals are more refractory to neutralization than TCLA strains, suggesting that qualitatively different neutralizing antibodies may be involved. In this study, we investigated whether the V3 loop constitutes a linear target epitope for antibodies neutralizing primary isolates. By using peptides representative of the V3 regions of various primary isolates, an early, relatively specific and persistent antibody response was detected in sera from HIV-infected patients. To assess the relationship between these antibodies and neutralization, the same peptides were used in competition and depletion experiments. Addition of homologous V3 peptides led to a competitive inhibition in the neutralization of the TCLA strain HIVMN/MT-4 but had no effect on the neutralization of the autologous primary isolate. Similarly, the removal of antibodies that bind to linear V3 epitopes resulted in a loss of HIVMN/MT-4 neutralization, whereas no decrease in the autologous neutralization was measured. The different roles of V3-specific antibodies according to the virus considered were thereby brought to light. This confirmed the involvement of V3 antibodies in the neutralization of a TCLA strain but emphasized a more pronounced contribution of either conformational epitopes or epitopes outside the V3 loop as targets for antibodies neutralizing primary HIV-1 isolates. This result underlines the need to focus on new vaccinal immunogens with epitopes able to induce broadly reactive and efficient antibodies that neutralize a wide range of primary HIV-1 isolates.


Subject(s)
Epitopes/genetics , HIV Antibodies , HIV Antigens/genetics , HIV Envelope Protein gp120/immunology , HIV-1/immunology , Peptide Fragments/immunology , Adaptation, Physiological , Amino Acid Sequence , Antibody Specificity , Base Sequence , Binding, Competitive , Cell Line , DNA Primers/genetics , HIV Envelope Protein gp120/genetics , HIV Infections/immunology , HIV Infections/virology , HIV-1/genetics , HIV-1/isolation & purification , Humans , In Vitro Techniques , Molecular Sequence Data , Neutralization Tests , Peptide Fragments/genetics , T-Lymphocytes/virology
6.
AIDS Res Hum Retroviruses ; 13(1): 19-27, 1997 Jan 01.
Article in English | MEDLINE | ID: mdl-8989423

ABSTRACT

Various studies have reported that primary human immunodeficiency viruses seem to be more refractory to neutralization by HIV-positive sera than T cell line-adapted strains. In this study we also show that adaptation of the HIV-1SF-2 strain, produced in PBMCs, to the cell line CEM-SS renders this isolate sensitive to neutralization by almost all the sera tested. Further neutralization studies should thus focus on the development of an assay involving primary isolates in order to detect antibodies having a neutralizing activity in vivo. Neutralization protocols currently use either an antibody end-point dilution assay, which combines a fixed inoculum of virus with serial dilutions of antibody, or an infectivity reduction assay, which uses serial dilutions of virus with a single dilution of antibody. We have developed an assay designed for studying the neutralization of primary isolates that combines these two approaches. Performing the assay on PBMCs allows all primary isolates to be analyzed, not just those multiplying in T cell lines. The neutralizing titer measured on PBMCs for human HIV-positive sera is low, but reproducible and independent of the virus titer in a given experiment. It can be increased about five-fold by changing the temperature and duration of virus-serum interaction (overnight at 4 degrees C instead of 1 hr at 37 degrees C). These results emphasize the need for a relevant neutralization assay involving primary isolates and primary cells for a better understanding of the role of humoral response in HIV infection.


Subject(s)
HIV Antibodies/blood , HIV-1 , Neutralization Tests/methods , Amino Acid Sequence , Animals , CD4-Positive T-Lymphocytes , Cells, Cultured , Cloning, Molecular , HIV Envelope Protein gp120/genetics , HIV Seropositivity/immunology , Humans , Immune Sera , Leukocytes, Mononuclear , Molecular Sequence Data , Pan troglodytes , Peptide Fragments/genetics , RNA, Viral/genetics , Sequence Alignment , Sequence Analysis, DNA , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL
...